Future Fields, a pioneering fly biotechnology company based in Edmonton, Canada, has successfully raised an impressive $2.2 million in funding to accelerate its mission of transforming scientific research and production through innovative biomanufacturing. Founded in 2018, Future Fields has developed the groundbreaking EntoEngine™, the world’s first synthetic biology system utilizing fruit flies for recombinant protein production. This unique platform not only promotes sustainability and ethical practices in biotechnology but also caters to various industries seeking efficient biomolecular tools to conduct significant scientific advancements. With this recent infusion of capital, Future Fields aims to further enhance its production capabilities, scale up operations, and expand its market reach to ensure the benefits of its technology are accessible to a broader array of scientific and industrial partners. The company's commitment to humility and environmental responsibility is reflected in its proud membership with 1% for the Planet, an organization dedicated to promoting smart environmental giving, as well as its participation in the United Nations Global Compact initiative. Future Fields is not just pushing the boundaries of biotechnology but is also dedicated to aligning its operations with universal human rights, labor, environmental, and anti-corruption principles. As the world becomes increasingly aware of the need for sustainable scientific practices, Future Fields is poised to lead the charge in creating solutions that benefit both humanity and the planet. To learn more about how Future Fields is revolutionizing the future of science, visit https://futurefields.io/.









